,NR 566 Final Exam | Advanced Pharmacology for Care
of the Family (2026) Actual Q&A PDF | Chamberlain
1. Which pharmacokinetic parameter is defined as the fraction of an administered drug
dose that reaches systemic circulation in an unchanged form?
A) Volume of distribution
B) Bioavailability
C) Clearance
D) Elimination half-life
Correct Answer: Bioavailability
Rationale: Bioavailability is the proportion of a drug that enters systemic circulation in
an active form, which is 100% for intravenous administration but often lower for oral
routes due to incomplete absorption and first-pass metabolism. Volume of distribution
describes the theoretical space for drug distribution, clearance measures the rate of
drug removal, and half-life is the time for plasma concentration to decrease by 50%.
2. A patient with cirrhosis is prescribed a medication that is highly protein-bound. The
nurse practitioner should anticipate which pharmacokinetic change?
A) Decreased free drug concentration requiring a dose increase
B) Increased free drug concentration requiring a dose reduction
C) No change in dosing because protein binding does not affect free drug
D) Increased metabolism requiring more frequent dosing
,Correct Answer: Increased free drug concentration requiring a dose reduction
Rationale: Cirrhosis reduces albumin synthesis, leading to fewer protein-binding sites
and a higher fraction of free (active) drug. This increases the risk of toxicity, so doses
must often be reduced. The other options misstate the relationship between protein
binding and drug activity.
3. Which organ is primarily responsible for the metabolism of most medications?
A) Kidneys
B) Liver
C) Lungs
D) Intestines
Correct Answer: Liver
Rationale: The liver contains the cytochrome P450 enzyme system, which is
responsible for metabolizing the majority of drugs. The kidneys are the primary organs
for drug excretion, while the lungs and intestines play lesser roles in drug metabolism.
4. A medication with a narrow therapeutic index requires which clinical approach?
A) Minimal monitoring due to a wide safety margin
B) Close monitoring of serum drug levels
, C) No special precautions during prescribing
D) Higher doses to ensure efficacy
Correct Answer: Close monitoring of serum drug levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic concentrations. Examples include warfarin, lithium, and digoxin,
which require careful monitoring of serum levels to avoid toxicity or treatment failure.
5. A patient is a CYP2D6 poor metabolizer. Which clinical consequence is most likely
when the patient receives a standard dose of a CYP2D6 substrate?
A) Reduced drug efficacy due to rapid metabolism
B) Increased risk of adverse effects due to drug accumulation
C) No change in drug response compared to normal metabolizers
D) Decreased plasma half-life requiring more frequent dosing
Correct Answer: Increased risk of adverse effects due to drug accumulation
Rationale: Poor metabolizers have reduced CYP2D6 enzyme activity, which slows drug
clearance and raises plasma concentrations of substrate drugs. This increases the risk of
dose-dependent adverse effects.
6. Grapefruit juice inhibits CYP3A4. A patient taking which medication should avoid
grapefruit juice?
of the Family (2026) Actual Q&A PDF | Chamberlain
1. Which pharmacokinetic parameter is defined as the fraction of an administered drug
dose that reaches systemic circulation in an unchanged form?
A) Volume of distribution
B) Bioavailability
C) Clearance
D) Elimination half-life
Correct Answer: Bioavailability
Rationale: Bioavailability is the proportion of a drug that enters systemic circulation in
an active form, which is 100% for intravenous administration but often lower for oral
routes due to incomplete absorption and first-pass metabolism. Volume of distribution
describes the theoretical space for drug distribution, clearance measures the rate of
drug removal, and half-life is the time for plasma concentration to decrease by 50%.
2. A patient with cirrhosis is prescribed a medication that is highly protein-bound. The
nurse practitioner should anticipate which pharmacokinetic change?
A) Decreased free drug concentration requiring a dose increase
B) Increased free drug concentration requiring a dose reduction
C) No change in dosing because protein binding does not affect free drug
D) Increased metabolism requiring more frequent dosing
,Correct Answer: Increased free drug concentration requiring a dose reduction
Rationale: Cirrhosis reduces albumin synthesis, leading to fewer protein-binding sites
and a higher fraction of free (active) drug. This increases the risk of toxicity, so doses
must often be reduced. The other options misstate the relationship between protein
binding and drug activity.
3. Which organ is primarily responsible for the metabolism of most medications?
A) Kidneys
B) Liver
C) Lungs
D) Intestines
Correct Answer: Liver
Rationale: The liver contains the cytochrome P450 enzyme system, which is
responsible for metabolizing the majority of drugs. The kidneys are the primary organs
for drug excretion, while the lungs and intestines play lesser roles in drug metabolism.
4. A medication with a narrow therapeutic index requires which clinical approach?
A) Minimal monitoring due to a wide safety margin
B) Close monitoring of serum drug levels
, C) No special precautions during prescribing
D) Higher doses to ensure efficacy
Correct Answer: Close monitoring of serum drug levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic concentrations. Examples include warfarin, lithium, and digoxin,
which require careful monitoring of serum levels to avoid toxicity or treatment failure.
5. A patient is a CYP2D6 poor metabolizer. Which clinical consequence is most likely
when the patient receives a standard dose of a CYP2D6 substrate?
A) Reduced drug efficacy due to rapid metabolism
B) Increased risk of adverse effects due to drug accumulation
C) No change in drug response compared to normal metabolizers
D) Decreased plasma half-life requiring more frequent dosing
Correct Answer: Increased risk of adverse effects due to drug accumulation
Rationale: Poor metabolizers have reduced CYP2D6 enzyme activity, which slows drug
clearance and raises plasma concentrations of substrate drugs. This increases the risk of
dose-dependent adverse effects.
6. Grapefruit juice inhibits CYP3A4. A patient taking which medication should avoid
grapefruit juice?
